Verve TherapeuticsVerve Therapeutics
Verve Therapeutics

Verve Therapeutics

Developing gene editing therapies to lower cholesterol.

Website
2018Active
Advertise here

About

Verve Therapeutics is a biotechnology company focused on developing novel gene editing therapies to address cardiovascular disease. Their lead candidate, VERVE-102, is an experimental gene-editing therapy designed to permanently lower LDL cholesterol (bad cholesterol) after a single infusion. The therapy works by targeting PCSK9, a gene that plays a key role in regulating cholesterol levels. Early clinical trial results have shown promising safety and efficacy, with significant reductions in LDL cholesterol observed.

Technology stack

detected 2026-06-14
Est. monthly stack spend~$90/mo
CDN
Cloudflare
EmailMicrosoft 365
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Verve Therapeutics do?

Verve Therapeutics is a biotechnology company focused on developing novel gene editing therapies to address cardiovascular disease. Their lead candidate, VERVE-102, is an experimental gene-editing therapy designed to permanently lower LDL cholesterol (bad cholesterol) after a single infusion. The therapy works by targeting PCSK9, a gene that plays a key role in regulating cholesterol levels. Early clinical trial results have shown promising safety and efficacy, with significant reductions in LDL…

How much funding has Verve Therapeutics raised?

Verve Therapeutics has raised a total of $300M in funding. The most recent round on record is Series D.

Where is Verve Therapeutics headquartered?

Verve Therapeutics is headquartered in Cambridge, Massachusetts, USA.

When was Verve Therapeutics founded?

Verve Therapeutics was founded in 2018.

What industry does Verve Therapeutics operate in?

Verve Therapeutics operates in Biotechnology, Gene Therapy, Cardiovascular Disease, Drug Delivery, Biotech, MedTech.